Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Genentech announced FDA approval of ranibizumab injection (Susvimo) for diabetic retinopathy -- the continuous delivery treatment is for patients who have already responded to anti-VEGF injections.

A surgical liaison in the operating room as a coach may ensure better surgical outcomes. He advised, “Watch Genentech’s surgical videos, be fully aware of all the surgical steps, and refer to them in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Ph ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. The workforce reduction will be complete by July 14, according to a California ...

SOUTH SAN FRANCISCO, Calif., June 02, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq ...

SOUTH SAN FRANCISCO, Calif., May 30, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, 96-week data for fenebrutinib demonstrating that patients with ...

On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

Biotechnology company Genentech announced plans to build its first East Coast manufacturing facility in Holly Springs, North Carolina. With an initial investment of over $700 million, the 700,000 ...